Business
Palatin Technologies Announces Closing of Reduced Public Offering
Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the "Se
About this update from Palatin Technologies, Inc.
[{"type":"text","content":"Company Transitioned onto the OTC Pink","length":38,"tagName":"p","attribs":{}},{"type":"text","content":"CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the "Series F Warrants"), Series G warrants to purchase up to 7,324,119 shares of common stock (the "Series G Warrants"), and Series H warrants to purchase up to 7,324,119 shares of common stock (the "Series H Warrants"), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the "Offering").","length":933,"tagName":"p"},{"type":"image","alt":"Palatin Technologies, Inc.","displaySize":"","headline":null,"caption":"Palatin Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":345,"url":"https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AQfwD723Z4IUxlX8GukUvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYwODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc","width":400,"height":345}},"href":"https://mma.prnewswire.com/media/464561/Palatin_Technologies_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Series F Warrants have an exercise price of $0.30 per share, are immediately exercisable and expire on the five-year anniversary of the original issuance date, subject to the certain terms as defined in such warrant. The Series G Warrants have an exercise price of $0.15 per share, are immediately exercisable and expire on the earlier of (i) the 24-month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period (as such term is defined in the Series G Warrant). The Series H Warrants will be issuable to the holder upon their exercise of the Series G Warrants, will have an exercise price of ...